Peel Hunt restated their buy rating on shares of Sensyne Health (LON:SENS) in a research note published on Thursday, ThisIsMoney.Co.Uk reports.
Several other equities research analysts also recently issued reports on the company. Peel Hunt reiterated a buy rating and set a GBX 262 ($3.42) price target on shares of Sensyne Health in a report on Thursday, October 10th. Liberum Capital restated a buy rating on shares of Sensyne Health in a research note on Friday, November 15th.
LON:SENS opened at GBX 88.50 ($1.16) on Thursday. The firm has a market capitalization of $113.79 million and a PE ratio of -4.78. The company has a current ratio of 13.92, a quick ratio of 13.81 and a debt-to-equity ratio of 3.07. Sensyne Health has a 1 year low of GBX 85 ($1.11) and a 1 year high of GBX 190 ($2.48). The firm’s fifty day simple moving average is GBX 106.61 and its 200 day simple moving average is GBX 129.86.
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts.
Recommended Story: What impact do institutional investors have on markets?
Receive News & Ratings for Sensyne Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensyne Health and related companies with MarketBeat.com's FREE daily email newsletter.